Expert Interview
Looking at the recent Phase 3 results on Scholar Rock's apitegromab for Spinal Muscular Atrophy
Ticker(s): SRRK, RHHBF, BHVN, BIIBInstitution: Duke University
- Former Co-Director of Duke Children's Neuromuscular Program & Professor of Neurology and Pediatrics at Duke, recently made a career change and is now exclusively focused on clinical trials.
- Treated hundreds of neuromuscular patients, including 150 DMD patients of all ages in 2023
- Actively involved in clinical research and many trials with a focus on pedicatric neuromuscular diseases; PI on multiple DMD studies including an Exon 53 skipping specific study.
Roughly how many patients with type 2/3 SMA do you treat?
Added By: ben_adminHow do you tend to treat type 2 patients? Type 3?
Added By: ben_adminWhat are your high level thoughts on apitegromab?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
